SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway - PubMed
4 hours ago
- #Mitochondrial homeostasis
- #Heart failure
- #SGLT2 inhibitor
- Dapagliflozin, an SGLT2 inhibitor, improves diastolic function and reduces cardiac hypertrophy, fibrosis, and apoptosis in a rat model of HFpEF.
- The drug restores mitochondrial structure and function, enhancing mitochondrial respiratory capacity in cardiomyocytes in both in vivo and in vitro models.
- Mechanistic studies show dapagliflozin reactivates the suppressed SIRT1/PGC-1α/Mitofusin-2 signaling axis in HFpEF, promoting mitochondrial biogenesis and dynamics.
- This reveals that dapagliflozin's cardioprotective effects in HFpEF are mediated through mitochondrial homeostasis restoration via the SIRT1/PGC-1α/Mfn-2 pathway.